Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18–25 years: Results from a randomized controlled trial

Benzer Materyaller

• Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years: Results from 2 randomized controlled trials
  Yazar:: Zhu, Fengcai, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• Efficacy, immunogenicity, and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in Chinese women aged 18–25 years: event‐triggered analysis of a randomized controlled trial
  Yazar:: Zhu, Feng‐cai, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)
• Efficacy of the AS04-adjuvanted HPV-16/18 vaccine in young Chinese women with oncogenic HPV infection at baseline: post-hoc analysis of a randomized controlled trial
  Yazar:: Hu, Shangying, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18–45 years
  Yazar:: Einstein, Mark H, ve diğerleri
  Baskı/Yayın Bilgisi: (2011)
• Efficacy, immunogenicity and safety of the AS04‐HPV‐16/18 vaccine in Chinese women aged 18‐25 years: End‐of‐study results from a phase II/III, randomised, controlled trial
  Yazar:: Zhu, Feng‐Cai, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)